Nf2 (Schwannomin)のexon2の両側にloxPが挿入されているマウス。 条件を付加する。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。Genes Dev., 14, 1617-1630 (2000).<br>研究成果の公表にあたって謝辞の表明を必要とする。<br>RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the "Invention") RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR's internal use.<br>RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party's inventiveness contribution in the Invention.<br>In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters. 開発者／機関：INSERM U674開発年：1998年FVB/Nに10代backcrossした後、intercrossにて維持。 Developed by Drs. Marco Giovannini and Gilles Thomas in INSERM at 1988. Strain of Origin: 129P2/OlaHsd-Hprt1<b-m3> via HM-1 ES cell line. FVB background. FVB.129P2-Nf2<tm2Gth> FVB.129P2-Nf2<tm2Gth> Nf2, neurofibromatosis 2 is a tumor suppressor gene encoding a putative cytoskeletal associated protein. This conditional knockout mice have a loxP-flanked Nf2 allele. Conditional Nf2 deficient mice can be generated by crossing with tissue-specific Cre mice. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Genes Dev., 14, 1617-1630 (2000).In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the "Invention") RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR's internal use.<br>RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party's inventiveness contribution in the Invention.<br>In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters. Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> phage P1 loxP sites, mouse Nf2 genomic DNA Sibling Mating (Homozygote x Homozygote, Heterozygote) Homozygous mutant mice are viable and fertile. Marco Giovannini Marco Giovannini B（1〜3か月） RBRC02344 true B (1-3 months) <a href='https://brc.riken.jp/mus/pcr02344'>Genotyping protocol -PCR-</a> Cre/loxP system Nf2flox2 (FVB) Nf2flox2 (FVB) 開発者／機関：INSERM U674 開発年：1998年 FVB/Nに10代backcrossした後、intercrossにて維持。 Sibling Mating (Homozygote x Homozygote, Heterozygote)Homozygous mutant mice are viable and fertile. 兄妹交配 INSERM INSERM